Services
Regulatory-first, payer-aligned market optimization
Capital
Access
Commercial
Capabilities
Regulatory
Compliance
Clinical
Expertise
Health Innovation For Patients
What We Do
Synovathera partners with innovators, from Venture-backed Biotechs to Global Pharma, Digital Health, AI enabled SaMD, Advanced Diagnostics and Medtech, to bring therapies to Canadian patients. We deliver integrated, payer-aligned solutions across the product lifecycle for lasting value to patients, prescribers, channel partners, and payers
Our Mission
We expand patient access to life-changing therapies by aligning regulatory strategy, payer evidence, and go-to-market execution. Synovathera bridges clinical promise to reimbursed access.
What We Deliver
-
In-Licensing & Strategic Partnerships (Pharma, Biologics, AI-enabled SaMD, Medtech, Advanced Diagnostics)
-
Full-Service Commercialization (launch planning & GTM, MSL/key accounts, clinical/HEOR, payer dossiers & HTA)
-
Clarity Intelligence™ (Monte Carlo scenarios, price corridors, indication sequencing, pilot→payer conversion tracking)
Why Us for Canada
-
Built for CDA/INESSS, PMPRB, pCPA, provincial formularies, PSPs
-
High-trust network with KOLs, payers, PSPs, distributors, and policy leaders
-
Outcomes over overhead—lean commercialization that converts pilots to paid coverage
Who We Work With
Global innovators, investors validating pipeline readiness, HealthTech needing local infrastructure, and commercial teams seeking execution without a full buildout.
Outcomes
-
Faster time-to-access
-
Lower pricing/reimbursement risk
-
Higher forecast accuracy
-
Quicker path to cash-positive operations in Canada
Leadership
Hands-on success across GTM, regulatory strategy, clinical development, and commercialization, spanning breakthrough and mature portfolios.
Frequently Asked Questions
1. We in-license and commercialize therapies for Canada. What does that mean?
We partner with global biopharma, medtech, and digital health companies to launch in Canada—handling regulatory, reimbursement, PSP, and commercial execution under licensing or BOT models.
2. Who is a good fit for Synovathera?
Companies with validated products, approved or close to launch looking to enter Canada quickly, without building local infrastructure.
3. How are you different from other commercial partners?
combine regulatory-first execution with payer strategy and scenario-based modeling (Clarity Intelligence™) to cut time-to-access and de-risk market entry.
4. What services do you offer?
End-to-end support: regulatory submissions, HTA/pCPA strategy, PSP design, distribution setup, KOL engagement, and GTM launch execution.
5. Can you act as our Canadian licensee or distributor?
Yes. We offer licensing, co-promotion, or BOT models to commercialize your product and manage all local operations.
6. How do you accelerate reimbursement and access?
We align regulatory and payer strategies early, design PSPs to support adoption, and use modeling to prioritize high-impact pathways.
7. Do you only work with drugs?
No. We also support diagnostics, SaMD, and AI-health tools requiring Health Canada approval, reimbursement, or clinical integration.
8. How long does it take to launch in Canada?
Regulatory + pricing timelines vary. Most launches take 9–18 months—faster with upfront alignment and execution readiness.
9. What does a typical engagement look like?
Start with a 30-min call → intake brief → roadmap in 2–3 weeks. We then execute under a structured licensing or services agreement.
10. Do you work with startups or venture-backed companies?
Yes. We help Seed to Series C teams validate PMF, design Canada-first strategies, and execute faster without internal distraction.
11. How do you charge?
Flexible: milestone retainers, revenue share, or licensing rights depending on asset maturity and engagement model.
12. How do we get started?
Book a call, send your deck, and we’ll scope a roadmap to Canadian commercialization.